Company news

MiMedx Group, Inc news in 2022

MiMedx Group, Inc's news releases, calls and decks from 2022, newest first.

View company

MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics

December 7, 2022

MIMEDX Announces Third Quarter 2022 Operating and Financial Results

November 1, 2022

MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2

October 18, 2022

MIMEDX Appoints Matt Notarianni as Head of Investor Relations

October 3, 2022

MIMEDX Announces Launch of AXIOFILL™

September 19, 2022

MIMEDX Announces Launch of AMNIOEFFECT™

September 18, 2022

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

September 11, 2022

MIMEDX Announces Leadership Transition

September 5, 2022

MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 3, 2022

MIMEDX Announces Second Quarter 2022 Operating and Financial Results

August 1, 2022

MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

July 26, 2022

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

July 19, 2022

MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

July 17, 2022

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

June 14, 2022

MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

June 6, 2022

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

June 2, 2022

MIMEDX Addresses Presentation by Prescience Point

June 1, 2022

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

May 30, 2022

MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders

May 30, 2022

Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

May 24, 2022

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

May 19, 2022

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

May 17, 2022

MIMEDX Mails Letter to Shareholders

May 15, 2022

MIMEDX Comments on Prescience Point’s False and Misleading Statements

May 8, 2022

MIMEDX to Participate at Upcoming Investor Conferences

May 4, 2022

MIMEDX Announces First Quarter 2022 Operating and Financial Results

May 2, 2022

MIMEDX Comments on Prescience Point’s Recent Filing

April 28, 2022

MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4

April 19, 2022

MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring

April 4, 2022

MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference

March 14, 2022

MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

February 27, 2022

Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care

February 15, 2022

MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28

February 13, 2022

MIMEDX Outlines Key Strategic Milestones for 2022

January 9, 2022

MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

Calls in 2022

Decks in 2022